HCA Healthcare (NYSE:HCA) Issues FY 2025 Earnings Guidance

HCA Healthcare (NYSE:HCA) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 24.050-25.850 for the period, compared to the consensus estimate of 24.610. The company issued revenue guidance of $72.8 billion-$75.8 billion, compared to the consensus revenue estimate of $74.8 billion.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on HCA. Barclays cut their price target on HCA Healthcare from $396.00 to $392.00 and set an “overweight” rating for the company in a report on Friday, November 8th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $380.00 price objective on shares of HCA Healthcare in a research note on Tuesday, December 17th. Truist Financial reduced their price target on shares of HCA Healthcare from $430.00 to $390.00 and set a “buy” rating for the company in a research report on Monday, January 6th. KeyCorp dropped their price objective on HCA Healthcare from $420.00 to $370.00 and set an “overweight” rating for the company in a research note on Tuesday, January 7th. Finally, StockNews.com downgraded HCA Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $385.27.

HCA Healthcare Price Performance

Shares of HCA stock opened at $325.18 on Friday. HCA Healthcare has a twelve month low of $278.68 and a twelve month high of $417.14. The business’s fifty day moving average is $314.50 and its 200 day moving average is $352.84. The stock has a market cap of $82.37 billion, a price-to-earnings ratio of 14.60, a PEG ratio of 1.09 and a beta of 1.64. The company has a quick ratio of 1.00, a current ratio of 1.12 and a debt-to-equity ratio of 48.71.

Insider Activity at HCA Healthcare

In other news, SVP Phillip G. Billington sold 3,897 shares of HCA Healthcare stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $350.00, for a total value of $1,363,950.00. Following the completion of the sale, the senior vice president now directly owns 52,702 shares in the company, valued at $18,445,700. The trade was a 6.89 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Erol R. Akdamar sold 2,900 shares of the firm’s stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $353.00, for a total transaction of $1,023,700.00. Following the completion of the sale, the insider now owns 6,843 shares in the company, valued at $2,415,579. This represents a 29.76 % decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.